Background: Following percutaneous coronary intervention (PCI) in patients with atrial fibrillation (AF) and CHA2DS2-VASc score ≥2, combination antiplatelet and oral anticoagulant (OAC) therapy is indicated. Dual therapy appears to be favorable to triple therapy with regard to bleeding; however, the optimal P2Y12 inhibitor remains in question. This study aimed to compare the safety and efficacy of second-generation P2Y12 inhibitors versus clopidogrel in combination with OAC in patients with AF undergoing PCI. Methods: The authors performed a systematic review including studies that compared dual and triple antithrombotic regimens for bleeding and major adverse cardiac events (MACE) in patients with AF undergoing PCI. The authors analyzed ra...
Background: New randomized, controlled trials have become available on oral P2Y12inhibitors in acute...
Background: The optimal antithrombotic strategy, especially regarding oral anticoagulants (OACs) for...
AIMS: To investigate the safety and efficacy of double vs. triple antithrombotic therapy (DAT vs. TA...
OBJECTIVE: This study aimed to compare the safety and efficacy of third-generation P2Y12 inhibitors ...
This study aimed to compare the safety and efficacy of third-generation P2Y12 inhibitors versus clop...
Background: In patients with atrial fibrillation (AF) receiving percutaneous coronary intervention (...
PURPOSE: Effective platelet inhibition prior to elective percutaneous coronary intervention (PCI) re...
Background: Patients with atrial fibrillation undergoing percutaneous coronary intervention have ind...
AIMS: Guidelines recommend the use of potent P2Y12 inhibitors over clopidogrel for the reduction of ...
<p>The risk and benefit of GP-IIb/IIIa Inhibition (GPI) in combination with recent antiplatelet regi...
OBJECTIVES The purpose of this study was to determine whether bleeding risk varies depending on whic...
The coexistence of coronary artery disease and atrial fibrillation (AF) in the same individuals rais...
Identifying the most appropriate antiplatelet therapy for each patient to prevent ischemic events wh...
Background:Each year it is estimated that 635,000 Americans have a primary coronary event, defined a...
Aims: To investigate the safety and efficacy of double vs. triple antithrombotic therapy (DAT vs. TA...
Background: New randomized, controlled trials have become available on oral P2Y12inhibitors in acute...
Background: The optimal antithrombotic strategy, especially regarding oral anticoagulants (OACs) for...
AIMS: To investigate the safety and efficacy of double vs. triple antithrombotic therapy (DAT vs. TA...
OBJECTIVE: This study aimed to compare the safety and efficacy of third-generation P2Y12 inhibitors ...
This study aimed to compare the safety and efficacy of third-generation P2Y12 inhibitors versus clop...
Background: In patients with atrial fibrillation (AF) receiving percutaneous coronary intervention (...
PURPOSE: Effective platelet inhibition prior to elective percutaneous coronary intervention (PCI) re...
Background: Patients with atrial fibrillation undergoing percutaneous coronary intervention have ind...
AIMS: Guidelines recommend the use of potent P2Y12 inhibitors over clopidogrel for the reduction of ...
<p>The risk and benefit of GP-IIb/IIIa Inhibition (GPI) in combination with recent antiplatelet regi...
OBJECTIVES The purpose of this study was to determine whether bleeding risk varies depending on whic...
The coexistence of coronary artery disease and atrial fibrillation (AF) in the same individuals rais...
Identifying the most appropriate antiplatelet therapy for each patient to prevent ischemic events wh...
Background:Each year it is estimated that 635,000 Americans have a primary coronary event, defined a...
Aims: To investigate the safety and efficacy of double vs. triple antithrombotic therapy (DAT vs. TA...
Background: New randomized, controlled trials have become available on oral P2Y12inhibitors in acute...
Background: The optimal antithrombotic strategy, especially regarding oral anticoagulants (OACs) for...
AIMS: To investigate the safety and efficacy of double vs. triple antithrombotic therapy (DAT vs. TA...